Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases
- First Online:
- 13 Downloads
Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting. This study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line setting.
From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, China. The short-term efficacies and safeties were analyzed.
1. A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole group. 2. There were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3–4) months, and median OS was 18 (4–28) months. 3. There were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn’t occurred acnelike rash were 0% (0/3), the differences of ORR, DCR between two groups were insignificant different (P = 0.143). 4. There was no treatment-associated death and no cetuximab-associated discontinuation. The incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with chemotherapy.
The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe.
Key wordscetuximab non-small cell lung cancer (NSCLC) efficacy safety non-first line
Unable to display preview. Download preview PDF.
- 5.Cappuzzo, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. ECCO ESMO, 2009.Google Scholar
- 6.Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG). J Clin Oncol, 2008, 26: 427s(LBA8012).Google Scholar
- 10.Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol, 2007, 25: 5777–5784.CrossRefPubMedGoogle Scholar
- 14.Thatcher N, Linchy TJ, Butts CA, et al. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trails. WCLC 2009, oral presentation (abstract A3.7).Google Scholar
- 15.Lin H, Jiang J, Liang X, et al. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer, 2010 Feb 9 [Epub ahead of print].Google Scholar
- 25.Zhang YF, Chen ZW, Lu S. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer. Chin Med J (Engl), 2009, 122: 2472–2476.Google Scholar